1. Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, Hogendoorn P, Jimeno J, Evrard V, Van Glabbeke M, Judson I: A phase II study of ET-743/trabectedin (‘Yondelis’) for patients with advanced gastrointestinal stromal tumours. Eur J Cancer 40: 1327–1331, 2004
2. Casanova M, Casali PG, Sessa C, et al.: Phase II study of 3-hour infusion of ET-743 in pretreated adult and pediatric patients with advanced/recurrent sarcomas-preliminary results from the Sendo and Italian Sarcoma Group (Abstract). Med Pediatr Oncol 39: 257, 2002
3. Dileo P, Casali PG, Bacci G, et al.: Phase II evaluation of 3-hr infusion ET-743 in patients with recurrent sarcomas (Abstract). Proc Am Soc Clin Oncol 21: 408a, 2002
4. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22: 1480-1490, 2004
5. George S, Maki RG, Harmon D, Supko J, Morgan J, Seiden M, Buonanno M, Griffin J, Moutsiolis A, Lopez T, Guzman C, Jimeno J, Demetri GD: Phase II study of ecteinascidin-743 (ET-743) given by 3-hour IV infusion in patients (pts) with soft tissue sarcomas (STS) failing prior chemotherapies (Abstract). Proc Am Soc Clin Oncol 21: 408a, 2002